Phase 1 First in Human Study of ZN-d5 as a Single Agent
Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 dose escalation, open label, multicenter study, evaluating the safety,
tolerability, clinical activity, pharmacokinetics (PK) and pharmacodynamics (PD) of ZN-d5 in
subjects with Non-Hodgkin Lymphoma (NHL) and subjects with Acute Myeloid Leukemia (AML).